. Author manuscript; available in PMC: 2014 Oct 1.

Published in final edited form as: Cancer Chemother Pharmacol. 2013 Aug 22;72(4):10.1007/s00280-013-2263-1. doi: 10.1007/s00280-013-2263-1

Table 2.

Comparison of drug delivery and toxicity in published phase II-III studies of adjuvant chemotherapy (vinorelbine plus docetaxel, cisplatin plus vinorelbine, cisplatin plus docetaxel)

	Cisplatin %		Vinorelbine %		Docetaxel %		Grade 3/4 hematologic toxicity (%)	Grade 3/4 non-heme toxicity (%)
	4 cycles	Dose intensity	4 cycles	Dose intensity	4 cycles	Dose intensity	Grade 3/4 hematologic toxicity (%)	Grade 3/4 non-heme toxicity (%)
vin+doce	NA	NA	60	88	56	84 (60 mg/m²) 78 (45 mg/m²)	64	52
JBR.10⁷	50	84	50	52	NA	NA	73	15 fatigue 17 n/v 8 infection
ANITA⁴	49	85	50	56	NA	NA	85	28 asthenia 27 n/v 20 infection
MSKCC cis+doce⁸	44	75	NA	NA	NR	NR	15	44

abbreviations: n/v (nausea and/or vomiting); NA (not applicable), NR (not reported); vin (vinorelbine); doce (docetaxel); cis (cisplatin)